Impact of Generic Dorzolamide Hydrochloride Approval on Glaucoma Market Dynamics
Ophthalmology · Glaucoma • Regulatory Approval • Jun 22, 2026
Assessment confidence: 40% · The main uncertainty is whether medium-relevance evidence fully captures sub-indication-specific dynamics.
Executive Thesis
The FDA's grant of Abbreviated Approval for a generic version of Dorzolamide Hydrochloride by FDC LTD introduces significant competitive pressure in the glaucoma treatment market. This could lead to pricing changes and market share shifts for existing branded products, necessitating close monitoring by portfolio teams. Regulatory context from FDA (FDA AP — DORZOLAMIDE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 2 ranked evidence items (0 high-relevance).
Strategic Assessment
Portfolio teams should assess the impact of this new generic on pricing and market share for existing branded products in the glaucoma category. The strongest clinical anchor is A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In ophthalmology, 1 regulatory and 1 competitive items passed relevance filtering for FDC LTD.
Competitive Pressure
The most relevant competitive pressure comes from FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement (Humanexa Signals) — sponsor/company relevance (pfizer). This approval allows FDC LTD to enter the market with a generic version of Dorzolamide Hydrochloride, potentially increasing competition in the glaucoma treatment space.
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — DORZOLAMIDE HYDROCHLORIDE (SUPPL) (FDA). Entity match (fdc ltd); Regulatory pathway relevance (nda). The approval signifies compliance with FDA standards but does not indicate any changes to existing regulatory frameworks for other products.
Key Risks
- Potential pricing wars that could diminish profit margins across the glaucoma treatment market.
- Regulatory uncertainties surrounding future approvals that may further alter competitive dynamics.
- Competitive pressure on FDC LTD: This approval allows FDC LTD to enter the market with a generic version of Dorzolamide Hydrochloride, potentially increa.
Key Opportunities
- The entry of a generic competitor may erode the market share and pricing power of established brands in the glaucoma category, impacting revenue streams.
- Portfolio teams should assess the impact of this new generic on pricing and market share for existing branded products in the glaucoma category.
What Would Change This Assessment
- This becomes more urgent if Monitor market entry timing and pricing strategies of FDC LTD post-approval.
- Additional medium- or high-relevance evidence would materially upgrade this assessment.
- Timeline shift beyond near term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — DORZOLAMIDE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (fdc ltd); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — HYDROXYZINE HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — VALACYCLOVIR HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — CYCLOBENZAPRINE HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceStatus Epilepticus Population Study (STEPS)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceGemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffect of MEMOPTIC on Visual Field of Patients Followed for Chronic Open-angle Glaucoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCollection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
No evidence in this category.
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceImmune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceTwo-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceOro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Related Signals
- FDA Grants AP Status for Dorzolamide Hydrochloride ANDA205294
Regulatory Approval
Related Regulatory Precedents
FDA
FDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)
Application ANDA204982. Sponsor: ACTAVIS LABS FL INC. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: PHENTERMINE HYDROCHLORIDE, TOPIRAMATE.
SourceFDA
FDA AP — DEXMEDETOMIDINE HYDROCHLORIDE (SUPPL)
Application NDA206628. Sponsor: HQ SPCLT PHARMA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: DEXMEDETOMIDINE HYDROCHLORIDE.
SourceFDA
FDA TA — VILOXAZINE HYDROCHLORIDE (ORIG)
Application ANDA220326. Sponsor: APPCO PHARMA LLC. Submission status: TA. Submission type: ORIG. Review priority: STANDARD. Active ingredients: VILOXAZINE HYDROCHLORIDE.
SourceFDA
FDA AP — CYCLOBENZAPRINE HYDROCHLORIDE (SUPPL)
Application ANDA072854. Sponsor: AIPING PHARM INC. Submission status: AP. Submission type: SUPPL. Review priority: UNKNOWN. Active ingredients: CYCLOBENZAPRINE HYDROCHLORIDE.
SourceFDA
FDA AP — VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER (SUPPL)
Application NDA050671. Sponsor: BAXTER HLTHCARE. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: VANCOMYCIN HYDROCHLORIDE.
Source